Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia

被引:53
作者
Andren, L.
Andreasson, A.
Eggertsen, R.
机构
[1] Gothenburg Univ, Sahlgrenska Univ Hosp, Dept Med Clin Pharmacol, S-41345 Gothenburg, Sweden
[2] Gothenburg Univ, Dept Med Primary Hlth Care, Gothenburg, Sweden
关键词
St. John's wort; hypericum perforatum; atorvastatin; interaction; LDL cholesterol;
D O I
10.1007/s00228-007-0345-x
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Objective The aim of this study was to assess the effect of treatment with a St. John's wort product (Movina) on cholesterol [total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol] and triglyceride levels in patients with hypercholesterolemia on treatment with a stable dose of atorvastatin in a controlled, randomised, open, crossover interaction study. Methods Sixteen patients with hypercholesterolemia treated with a stable dose of atorvastatin (10-40 mg/daily) for at least 3 months were treated with Movina one tablet (containing 300 mg of hypericum perforatum) twice daily and control (a commercially available multivitamin tablet Vitamineral). After a run-in period of 4 weeks, patients were randomised to treatment with either Movina or control for 4 weeks in a crossover design. The atorvastatin dose was kept unchanged during the study period (12 weeks), and assessments of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were performed in the morning with the patients in the fasting condition. The difference between control and active treatment in LDL cholesterol after 4 weeks of treatment was the primary endpoint. Results All patients completed the study. The St. John's wort product significantly increased the serum level of LDL cholesterol compared with control (2.66 mmol/l compared with 2.34 mmol/l, p=0.004). A significant increase in total cholesterol was also observed (5,10 mmol/l compared with 4.78 mmol/l, p=0.02). No statistically significant change was observed in HDL cholesterol (1.59 mmol/l and 1.56 mmol/l, p=0.49) or in triglycerides (1.87mmol/l and 1.94mmol/l, p=0.60). No product-related side effects were reported Conclusion An interaction was observed between the studied St.-John's-wort-containing product and atorvastatin. Physicians and patients should be aware of this interaction and if treatment with a St. John's wort product is considered necessary, then there may be a need for increasing the dose of atorvastatin.
引用
收藏
页码:913 / 916
页数:4
相关论文
共 14 条
[1]
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 [J].
Dürr, D ;
Stieger, B ;
Kullak-Ublick, GA ;
Rentsch, KM ;
Steinert, HC ;
Meier, PJ ;
Fattinger, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :598-604
[2]
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care - The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) [J].
Furberg, CD ;
Wright, JT ;
Davis, BR ;
Cutler, JA ;
Alderman, M ;
Black, H ;
Cushman, W ;
Grimm, R ;
Haywood, LJ ;
Leenen, F ;
Oparil, S ;
Probstfield, J ;
Whelton, P ;
Nwachuku, C ;
Gordon, D ;
Proschan, M ;
Einhorn, P ;
Ford, CE ;
Piller, LB ;
Dunn, JK ;
Goff, D ;
Pressel, S ;
Bettencourt, J ;
deLeon, B ;
Simpson, LM ;
Blanton, J ;
Geraci, T ;
Walsh, SM ;
Nelson, C ;
Rahman, M ;
Juratovac, A ;
Pospisil, R ;
Carroll, L ;
Sullivan, S ;
Russo, J ;
Barone, G ;
Christian, R ;
Feldman, S ;
Lucente, T ;
Calhoun, D ;
Jenkins, K ;
McDowell, P ;
Johnson, J ;
Kingry, C ;
Alzate, J ;
Margolis, KL ;
Holland-Klemme, LA ;
Jaeger, B ;
Williamson, J ;
Louis, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (23) :2998-3007
[3]
Role of P-glycoprotein in statin drug interactions [J].
Holtzman, Carol W. ;
Wiggins, Barbara S. ;
Spinler, Sarah A. .
PHARMACOTHERAPY, 2006, 26 (11) :1601-1607
[4]
Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's Wort (Hypericum perforatum) [J].
Johne, A ;
Schmider, J ;
Brockmöller, J ;
Stadelmann, AM ;
Störmer, E ;
Bauer, S ;
Scholler, G ;
Langheinrich, M ;
Roots, I .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (01) :46-54
[5]
Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J].
LaRosa, JC ;
Grundy, SM ;
Waters, DD ;
Shear, C ;
Barter, P ;
Fruchart, J ;
Gotto, AM ;
Greten, H ;
Kastelein, JJP ;
Shepherd, J ;
Wenger, NK .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) :1425-1435
[6]
Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme [J].
Markowitz, JS ;
Donovan, JL ;
DeVane, CL ;
Taylor, RM ;
Ruan, Y ;
Wang, JS ;
Chavin, KD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (11) :1500-1504
[7]
Interaction of St John's wort with conventional drugs: systematic review of clinical trials [J].
Mills, E ;
Montori, VM ;
Wu, P ;
Gallicano, K ;
Clarke, M ;
Guyatt, G .
BRITISH MEDICAL JOURNAL, 2004, 329 (7456) :27-30
[8]
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis - A randomized controlled trial [J].
Nissen, SE ;
Tuzcu, EM ;
Schoenhagen, P ;
Brown, BG ;
Ganz, P ;
Vogel, RA ;
Crowe, T ;
Howard, G ;
Cooper, CJ ;
Brodie, B ;
Grines, CL ;
DeMaria, AN .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (09) :1071-1080
[9]
Indinavir concentrations and St John's wort [J].
Piscitelli, SC ;
Burstein, AH ;
Chaitt, D ;
Alfaro, RM ;
Falloon, J .
LANCET, 2000, 355 (9203) :547-548
[10]
Acute heart transplant rejection due to Saint John's wort [J].
Ruschitzka, F ;
Meier, PJ ;
Turina, M ;
Lüscher, TF ;
Noll, G .
LANCET, 2000, 355 (9203) :548-549